SC
FLXN

Scholtz & Company’s Flexion Therapeutics, Inc. FLXN Stock Holding History

Scholtz & Company’s Portfolio FLXN Stock Details FLXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-41,675
Closed -$1.08M – 60
2018
Q2 		$1.08M Sell
41,675
-45,800
-52% -$1.19M 0.75% 31
2018
Q1 		$1.96M Buy
87,475
+1,100
+1% +$26.8K 1.45% 33
2017
Q4 		$2.16M Buy
86,375
+31,125
+56% +$762K 1.57% 30
2017
Q3 		$1.34M Sell
55,250
-705
-1% -$16.6K 1.05% 35
2017
Q2 		$1.13M Buy
+55,955
New +$1.17M 0.98% 41

Other funds holding FLXN

MVP
Miller Value Partners Sarasota, Florida $423M AUM 49.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Scholtz & Company's FLXN Position: Q3 2018 in Review

Scholtz & Company sold out of Flexion Therapeutics, Inc. (FLXN) in Q3 2018, closing a stake of 41,675 shares — an estimated $1.08M sold.

Scholtz & Company first reported a position in FLXN in Q2 2017 and held it in 5 quarters. The position peaked at $2.16M in Q4 2017. 129 funds tracked by Wall St. Rank hold FLXN as of Q3 2018.

  • Scholtz & Company reported no remaining Flexion Therapeutics, Inc. position as of Q3 2018 after selling out during the quarter.
  • Scholtz & Company sold 41,675 Flexion Therapeutics, Inc. shares in Q3 2018, an estimated $1.08M.
  • Scholtz & Company first reported a position in Flexion Therapeutics, Inc. in Q2 2017 and held it in 5 quarters.
  • Scholtz & Company's Flexion Therapeutics, Inc. position peaked at $2.16M in Q4 2017.
  • 129 funds tracked by Wall St. Rank held Flexion Therapeutics, Inc. as of Q3 2018.

Based on Scholtz & Company's 13F filing for Q3 2018, filed 14 Nov 2018.